Dr Reddy’s Recalls Ranitidine Tablets from Retail Counters in US


Oct. 23/2019 – Indian pharmaceutical company Dr. Reddy’s Laboratories recalled its ranitidine tablets from the retail counters located in the US due to high level of the carcinogen N-nitrosodimethylamine (NDMA). 

After the US Food and Drug Administration (FDA) had warned of the presence of the impurities in those tablets, Dr. Reddy’s initiated the recall process voluntarily, a filing submitted by the company said. 

As per scientific tests, the NDMA could cause cancer in humans as the substance is a known environmental contaminant which is mostly found in water and foods. 

Apart, the Drug Controller General of India issued a directive to all state regulators asking them to get manufacturers to test anti-acidity drug ranitidine for the impurity. The Hyderabad-based firm does not market this product in its home country. 


About Author

Leave A Reply